• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GYRE

    Gyre Therapeutics Inc.

    Subscribe to $GYRE
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2006

    Exchange: NASDAQ

    Recent Analyst Ratings for Gyre Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    3/11/2025Outperform
    Noble Capital Markets
    See more ratings

    Gyre Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B ("CHB")-associated liver fibrosis; currently reviewing data and on track to report topline results in Q2 2025Received IND approval from China's National Medical Products Administration ("NMPA") for a new indication of pirfenidone to treat radiation-induced lung injury ("RILI"), with or without immune-related pneumonitis ("CIP"), marking Gyre's first entry into oncology supportive care spaceInitiated commercialization of avatrombopag in China in March 2025, building a strategic presence with liver disease specialistsNin

      5/9/25 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

      SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical Products Administration (NMPA) of the People's Republic of China ("PRC") has approved its clinical trial application for a potential new indication for pirfenidone in oncology-related pulmonary complications. The trial will evaluate pirfenidone capsules for the treatment of radiation-induced lung injury (RILI), with or without immune-related pneumonitis (CIP). This regulatory milestone marks the expansion of pirfenidone beyond its established role in idiopathic pulmonary fibrosis (

      3/31/25 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

      SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication of the manuscript titled "Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized Trial" in the Journal of Clinical and Translational Hepatology. This publication details the full protocol for the pivotal Phase 3 trial to support the use of hydronidone in Chinese patients with liver fibrosis associated with chronic hepatitis B ("CHB"). The published protocol outlines patient inclusion criteria,

      3/27/25 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025 Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025 Full year 2025 total revenue guidance of $118 to $128 million SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced financial results for the fourth quarter and full

      3/17/25 4:15:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

      SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of Ping Zhang to its Board of Directors (the "Board") as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee of the Board. In addition, Ying Luo, Ph.D. resigned as Chairman and a member of the Board of Directors of Gyre and Gyre Pharmaceuticals, Gyre's majority indirectly owned subsidiary in the People's Republic of China ("PRC"), to focus on other responsibilities at GNI Grou

      1/6/25 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

      Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced f

      11/13/24 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

      SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that the last patient in Gyre Pharmaceuticals' pivotal Phase 3 trial in the People's Republic of China ("PRC") evaluating F351 (hydronidone) for Chronic Hepatitis B ("CHB")-associated liver fibrosis has completed the 52-week study. Gyre Pharmaceuticals expects to report topline data from this trial by the first quarter of 2025. "The final patient completing our pivotal F351 Phase 3 trial marks an important milestone for Gyre and our developm

      10/22/24 4:05:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

      SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the 8th Annual H.C. Wainwright MASH Investor Conference on Monday, October 7, 2024, at 2:30 PM ET (11:30 AM PT). The live webcast will be available on the Events and Presentations page of Gyre's website. A webcast replay will be accessible following the live session. About Gyre Therapeutics Gyre Therapeutics is a biopharmaceutical company headquartered in San D

      10/1/24 4:05:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

      SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 8:30 AM ET (5:30 AM PT). The live webcast will be available on the Events and Presentations page of Gyre's website. A webcast replay will be accessible following the live session. About Gyre Therapeutics Gyre Therapeutics is a biopharmaceutical company headqua

      9/4/24 4:05:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sidoti Events, LLC's Virtual August Micro-Cap Conference

      NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 14-15, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links. Presentation Schedule*All Times EDTWednesday, August 14, 2024 (Day 1)8:30-9:00*****Alta Global Group (MMA)Mobile-health Network (MNDR)9:15-9:45Steakholder Foods Ltd. (STKH)*****Regenx Tech (RGXTF)10:00-10:30*****Genius Group (GNS)*****10:45-11:15ARC Document Solutions (ARC)Xtract One Technologies (XTRA.TO)C

      8/13/24 9:30:00 AM ET
      $BYRN
      $CIA
      $COOT
      $DTIL
      Industrial Machinery/Components
      Miscellaneous
      Life Insurance
      Finance

    Gyre Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Gyre Therapeutics

      Noble Capital Markets initiated coverage of Gyre Therapeutics with a rating of Outperform

      3/11/25 10:02:24 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Gyre Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

      SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of Ping Zhang to its Board of Directors (the "Board") as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee of the Board. In addition, Ying Luo, Ph.D. resigned as Chairman and a member of the Board of Directors of Gyre and Gyre Pharmaceuticals, Gyre's majority indirectly owned subsidiary in the People's Republic of China ("PRC"), to focus on other responsibilities at GNI Grou

      1/6/25 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

      SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be

      8/8/24 4:05:00 PM ET
      $BDTX
      $GYRE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum

      SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the appointment of Rodney L. Nussbaum to the Company's Board of Directors and as a member of its Audit Committee. "Rodney has an extensive background in finance, accounting, and financial reporting with nearly four decades of experience working at global auditing and consulting firms," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "He joins our Board at a pivotal time as we advance our diversified pipeline of anti-fibrotic therapies. We look forwa

      3/21/24 7:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

      EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data. "We are thrilled by Nassim's arrival," said DCVC Bio Managing Pa

      12/15/23 9:04:00 AM ET
      $CBIO
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Gyre Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Ye Weiguo exercised 650,000 shares at a strike of $0.75 (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      4/25/25 4:01:13 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Eastling Thomas Wilson exercised 15,000 shares at a strike of $6.93 (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      4/18/25 5:27:15 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $1,740 worth of shares (174 units at $10.00) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      3/25/25 4:01:33 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $40,440 worth of shares (4,000 units at $10.11) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      3/21/25 4:01:48 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $26,658 worth of shares (2,242 units at $11.89) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      3/19/25 4:01:19 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $48,220 worth of shares (4,000 units at $12.05) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      3/17/25 4:01:39 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $46,280 worth of shares (4,000 units at $11.57) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      3/13/25 4:01:18 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Ye Weiguo

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      3/11/25 8:00:30 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $40,776 worth of shares (4,000 units at $10.19) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      3/11/25 4:01:45 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Ma Songjiang sold $43,560 worth of shares (4,000 units at $10.89) (SEC Form 4)

      4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

      3/7/25 4:02:06 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Gyre Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Gyre Therapeutics Inc.

      10-Q - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      5/9/25 4:30:37 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      5/8/25 8:30:09 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      4/28/25 7:05:24 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Gyre Therapeutics Inc.

      DEFA14A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      4/21/25 5:23:54 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Gyre Therapeutics Inc.

      DEF 14A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      4/21/25 5:23:02 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Gyre Therapeutics Inc.

      S-8 - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      3/20/25 4:01:44 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Gyre Therapeutics Inc.

      10-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      3/17/25 4:15:36 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      3/17/25 4:05:10 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      2/18/25 6:01:21 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

      1/6/25 7:05:30 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Gyre Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B ("CHB")-associated liver fibrosis; currently reviewing data and on track to report topline results in Q2 2025Received IND approval from China's National Medical Products Administration ("NMPA") for a new indication of pirfenidone to treat radiation-induced lung injury ("RILI"), with or without immune-related pneumonitis ("CIP"), marking Gyre's first entry into oncology supportive care spaceInitiated commercialization of avatrombopag in China in March 2025, building a strategic presence with liver disease specialistsNin

      5/9/25 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025 Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025 Full year 2025 total revenue guidance of $118 to $128 million SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced financial results for the fourth quarter and full

      3/17/25 4:15:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

      Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025 Commercial launch of avatrombopag maleate tablets expected by the first half of 2025 Commercial launch of nintedanib expected in 2025 Cash and cash equivalents totaled $15.9 million as of September 30, 2024 SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced f

      11/13/24 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

      Received NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, expanding rare disease product lines Received IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension U.S. IND submission for F351 in MASH-associated liver fibrosis expected in late 2024 and data readout from Phase 3 trial in CHB-associated liver fibrosis in the PRC expected by early 2025 Cash and cash equivalents totaled $16.1 million as of June 30, 2024 SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs f

      8/13/24 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

      Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC remains on track with data anticipated by early 2025 U.S. IND submission to evaluate F351 for the treatment of NASH-associated liver fibrosis expected in late 2024; Phase 2a trial expected to initiate in 2025 Acquired the rights to complementary assets relating to nintedanib through Gyre Pharmaceuticals to improve competitiveness in the PRC Cash and cash equivalents totaled $29.8 million as of March 31, 2024 SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic thera

      5/9/24 4:10:00 PM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

      Data readout from Phase 3 clinical trial in the People's Republic of China ("PRC") evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial evaluating F351 for the treatment of NASH-associated liver fibrosis planned for 2025 Appointed Dr. Han Ying as Chief Executive Officer Acquired indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd) as part of business combination agreement with GNI Cash and cash equivalents totaled $33.5 million as of December 31, 2023 SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre") (NASDAQ:GYRE), a cli

      3/26/24 6:00:00 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Gyre Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Gyre Therapeutics Inc.

      SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      9/6/24 8:31:07 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Gyre Therapeutics Inc.

      SC 13D - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

      9/6/24 8:15:45 AM ET
      $GYRE
      Biotechnology: Pharmaceutical Preparations
      Health Care